Literature DB >> 1559710

Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: application to aspartylglucosaminuria in Finland.

A C Syvänen1, E Ikonen, T Manninen, M Bengtström, H Söderlund, P Aula, L Peltonen.   

Abstract

Aspartylglucosaminuria (AGU) is a recessively inherited lysosomal disease caused by inadequate aspartylglucosaminidase (AGA) activity. The disease is prevalent in the genetically isolated Finnish population. We have used a new method, solid-phase minisequencing, to determine the frequency of two missense mutations in the AGA gene in this population. In samples from 70% of the Finnish AGU families, we found that the two nucleotide changes were always associated, and they were identified in 98% of the AGU alleles analyzed. Thus, the high prevalence of AGU in the Finnish population is the consequence of a founder effect of one ancient mutation. The identification of asymptomatic carriers by the minisequencing test proved to be unequivocal. The method also allowed quantification of a mutated nucleotide sequence present in less than 1% of a sample. The frequency of AGU carriers in this population was 1/36 when estimated by quantifying the mutated AGU allele in a pooled leukocyte sample from 1350 normal Finnish individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559710     DOI: 10.1016/0888-7543(92)90452-x

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  26 in total

1.  Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing.

Authors:  A Suomalainen; A C Syvänen
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

2.  A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays.

Authors:  T Pastinen; M Raitio; K Lindroos; P Tainola; L Peltonen; A C Syvänen
Journal:  Genome Res       Date:  2000-07       Impact factor: 9.043

Review 3.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

4.  Transglutaminase 1 mutations in autosomal recessive congenital ichthyosis: private and recurrent mutations in an isolated population.

Authors:  E Laiho; J Ignatius; H Mikkola; V C Yee; D C Teller; K M Niemi; U Saarialho-Kere; J Kere; A Palotie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

5.  Microsatellite instability in adenomas as a marker for hereditary nonpolyposis colorectal cancer.

Authors:  A Loukola; R Salovaara; P Kristo; A L Moisio; H Kääriäinen; H Ahtola; M Eskelinen; N Härkönen; R Julkunen; E Kangas; S Ojala; J Tulikoura; E Valkamo; H Järvinen; J P Mecklin; A de la Chapelle; L A Aaltonen
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

6.  Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay.

Authors:  C Delahunty; W Ankener; Q Deng; J Eng; D A Nickerson
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

7.  Rapid diagnostic test for the major mutation underlying Batten disease.

Authors:  I Järvelä; H M Mitchison; P B Munroe; A M O'Rawe; S E Mole; A C Syvänen
Journal:  J Med Genet       Date:  1996-12       Impact factor: 6.318

8.  Susceptibility-Weighted Imaging Findings in Aspartylglucosaminuria.

Authors:  A Tokola; M Laine; R Tikkanen; T Autti
Journal:  AJNR Am J Neuroradiol       Date:  2019-10-24       Impact factor: 3.825

9.  Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing.

Authors:  J Ihalainen; M Taavitsainen; T Salmivaara; A Palotie
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

10.  Solid-phase minisequencing confirmed by FISH analysis in determination of gene copy number.

Authors:  M Laan; K Grön-Virta; A Salo; P Aula; L Peltonen; A Palotie; A C Syvänen
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.